Moreover, plasma interleukin-6 (IL-6) has shown potential as a predictive biomarker in patients with advanced HCC receiving combination immunotherapy (Atezo/Bev) (Myojin et al., 2022). The gene discussed is IL6; the disease is hepatocellular carcinoma.